Micafungin: A new echinocandin antifungal

Pharmacotherapy

Volumn 27, Issue 1, 2007, Pages 53-67

  Joseph, Jomy M ^a   Jain, Rupali ^a   Danziger, Larry H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aspergillosis; Candidemia; Echinocandins; Esophageal candidiasis; Micafungin

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYTOCHROME P450 3A; FLUCONAZOLE; MICAFUNGIN;

ACUTE KIDNEY FAILURE; ANTIFUNGAL ACTIVITY; CANDIDA; CHILL; DIARRHEA; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; FUNGICIDAL ACTIVITY; HEADACHE; HEMOLYTIC ANEMIA; HISTAMINE RELEASE; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; INJECTION SITE REACTION; LEUKOPENIA; LIVER DISEASE; MYCOSIS; NAUSEA; PHLEBITIS; PRURITUS; RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG INTERACTIONS; ESOPHAGEAL DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIPOPROTEINS; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 33846073010     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.1.53     Document Type: Review

References (83)

1. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infection in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
3. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, for the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
4. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9.
5. Mora-Duarte J, Betts R, Rotstein R, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
6. Sable CA, Nguyen B-YT, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25-30.
7. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for the treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002;46:451-7.
8. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.
9. Villanueva A, Gotuzzo E, Arathoon E, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-9.
10. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
11. Astellas Pharma US. Mycamine (micafungin sodium) package insert. Deerfield, IL; 2005.
12. Astellas Pharma, Inc. Fugisawa updates the European development status of micafungin [press release]. September 3, 2004. Available from http://www.astellas.com/global/about/news/fugisawa/pdf/040903.pdf. Accessed March 27, 2006.
13. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57-62.
14. Mikamo H, Sato Y, Tamaya T. In vitro activity of FK-463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000;46:485-7.
15. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997;35:79-86.
16. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water soluble echinocandin-like lipopeptide. J Electron Microsc 2002;51:247-55.
17. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002;48:78-81.
18. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002;46:1857-69.
19. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003;47:1376-81.
20. Arikan S, Yurdakul P, Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother 2003;47:2640-3.
21. Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003;47:1995-8.
22. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp Isolates. Antimicrob Agents Chemother 2005;49:3264-73.
23. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57:705-8.
24. Serena C, Fernandez-Torres B, Pastor FJ, et al. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother 2005;49:2994-6.
25. Ingroff AE. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003;20:121-36.
26. Serena C, Marine M, Pastor FJ, Nolard N, Guarro J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces, and Rhodotorula. J Antimicrob Chemother 2005;55:1020-3.
27. Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005;49:5157-9.
28. Muller FM, Kurzai O, Hacker J, Frosch M, Muhlschlegel F. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 2001;48:713-15.
29. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47: 3149-54.
30. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002;50:119-23.
31. Takakura S, Fujihara N, Saito T, et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004;53:283-9.
32. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-6.
33. Chryssanthou E, Cuenca-Estrella M. Comparison of the antifungal susceptibility testing subcommittee of the European committee on antibiotic susceptibility testing proposed standard and the E-test with the NCCLS microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002;40:3841-4.
34. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2326-32.
35. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, Rinaldi MG. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999;18: 302-4.
36. Espinol-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunitistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36: 2950-6.
37. Serrano M, Valverde-Conde A, Chavez M, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003;45:131-5.
38. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents against bloodstream isolates of Candida spp. Diagn Microbiol Infect Dis 1998;31:33-7.
39. Arevalo MP, Carrillo-Munoz A, Salgado J, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003;51:163-6.
40. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006;44:324-6.
41. Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S. Efficacy of FK-463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000;44: 1728-30.
42. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp, including 315 isolates resistant to fluconazole. J Clin Microbiol 2005;43: 5425-7.
43. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005;49:3616-23.
44. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopetides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994;38:1480-9.
45. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001;45:327-30.
46. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assays to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001;45:3474-81.
47. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in immunocompromised mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005;49:4895-902.
48. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-43.
49. Graybill JR, Bocanegra R, Gonzalez G, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003;52:656-62.
50. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003;47:1452-5.
51. Nakajima M, Tamada, Yoshida K, et al. Pathological findings in a murine pulmonary aspergillosis model: treatment with FK463, amphotericin B and a combination of FK463 and amphotericin B [abstr and poster]. In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2000:387.
52. Kohno S, Maesaki S, Iwakawa J, et al. Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis [abstr and poster]. In: Program and abstracts of the 40th interscience conference of antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2000:388.
53. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 2004;10:925-8.
54. Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (Ambisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005;49:4867-75.
55. Ernst E, Roling E, Petzold CR, Keele DJ, Klepser ME. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002;46:3846-53.
56. Manavathu EK, Ramesh MS, Baskaran I, Ganesan L, Chandrasekar PH. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004;53:386-9.
57. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49: 3317-24.
58. Heimenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49:1331-6.
59. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005;45:1145-52.
60. Niwa T, Yokota Y, Tokunaga A, et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull 2004;27:1154-6.
61. Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001;45:3322-7.
62. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-9.
63. van Burik JH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.
64. Kishino S, Ohno K, Shimamura T, Furukawa H, Todo S. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 2004;18:676-80.
65. Mukai T, Ohkuma T, Nakahara K, Takaya T, Uematsu T, Azuma J. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects [abstr]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2001;5.
66. Heresi GP, Gerstmann DR, Blumer JL, et al. Pharmacokinetic, safety, and tolerance study of micafungin (FK463) in premature infants. Presented at the 2003 annual meeting of the Pediatric Academic Society, Seattle, WA, May 3-5, 2003.
67. de Wet N, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK-463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005;21:899-907.
68. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61.
69. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003;37:415-25.
70. Ostrosky-Zeichner L, Lashof AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:651-5.
71. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-8.
72. Ruhnke M, Kuse E, Chetchotisakd P, Arns Da Cuhna C, Diekmann-Berndt H. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis [abstr]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:M-722c.
73. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36:372-9.
74. Ullman AJ, van Burik J, McSweeney P, et al. An open phase II study of efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Presented at the 13th European congress of clinical microbiology and infectious diseases, Glasgow, United Kingdom, May 10-13, 2003.
75. Ratanatharathorn V, Flynn P, van Burik J, et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant patients [abstr]. In: Abstracts of the 44th annual meeting of the American Society of Hematology. Philadelphia: American Society of Hematology, 2002;627.
76. Ota S, Tanaka J, Kahata K, et al. Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study, Int J Hematol 2004;79:390-3.
77. Singer MS, Seibel NL, Vezina G, Choi SS, Dinndorf PA. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J Pediatr Hematol Oncol 2003;25:252-6.
78. Hebert MF, Blogh DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005;45:1018-24.
79. Undre N, Stevenson P, Amakye D. Rifampicin and ritonavir do not affect the pharmacokinetics of micafungin (FK463), an echinocandin antifungal. Presented at the 14th European congress of clinical microbiology and infectious diseases, Prague, Czech Republic, May 1-4, 2004.
80. Lin P, Mickiene D, Petraitis V, et al. Micafungin and amphotericin B have no pharmacokinetic interaction when used in combination therapy [abstr]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology 2004:M-227.
81. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporirie and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005;45:954-60.
82. Fleming T. Red book 2005. Montvale, NJ: Thomson PDR, 2005.
83. Merck & Co. Cancidas (caspofungin acetate for injection) prescribing information. Whitehouse Station, NJ; 2004.